Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms.
Affiliation
Department of Medicine, Faculty of Medicine, University of Porto, Porto, PortugalIssue Date
2016-02
Metadata
Show full item recordAbstract
Despite recent advances, prognosis of patients with advanced lung cancer remains dismal. Owing to a better understanding of the interactions between immune system and tumor cells, immunotherapy has emerged as a promising therapeutic strategy. After the recent approval of nivolumab and the promising results with other immune checkpoint inhibitors, combination strategies are now subject of intensive research. Notwithstanding these successes, immunotherapy still holds significant drawbacks. As the target shifts from tumor cells to the tumor microenvironment, treatment paradigms are changing and several improvements are needed for optimal use in clinical practice. Robust biomarkers for patient selection and a reliable way of evaluating treatment response are high priorities. Herein we review current data on immune checkpoint inhibitors for lung cancer treatment.Citation
Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms. 2016, 12 (4):551-64 Future OncolJournal
Future OncologyDOI
10.2217/fon.15.309PubMed ID
26776915Type
ArticleLanguage
enISSN
1744-8301ae974a485f413a2113503eed53cd6c53
10.2217/fon.15.309